COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 378 participants.
Also called NCT02404376
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 378 participants
- Registry
-
NCT02404376
-
- Other papers using this trial's data
- Spontaneous reperfusion enhances succinate concentration in peripheral blood from stemi patients but its levels does not correlate with myocardial infarct size or area at risk
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Spain
- Registry status
- Completed
Technical summary
Registry record NCT02404376. Randomized; double masking; primary purpose treatment. Start 2016-03 (actual); primary completion 2019-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial
- Acronym
- COMBAT-MI
- Condition
- ST Elevation Acute Myocardial Infarction
- Intervention (Drug)
- Exenatide
- Intervention (Other)
- Remote Ischemic Conditioning (RIC)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Record details
- Record id
cardio:ct-nct02404376- Content hash
5b4359f385e0612979295b85d7af429befcf6a0f17a5f9eae41f12d4bef4a7a7